• Are We Too Risk Averse in Clinical Research?

  • 2024/05/29
  • 再生時間： 45 分
  • ポッドキャスト

Are We Too Risk Averse in Clinical Research?

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • This week, Richard Young speaks to Ken Getz, executive director and research professor at Tufts Center for the Study of Drug Development.


    Already well-known in our industry for his pioneering research on protocol design complexity and trial efficiency, Ken’s most recent study found that the average number of amendments per protocol increased by almost 60% over the past seven years.


    In this episode, Richard and Ken debate whether clinical research is striking the right balance in its approach to risk and innovation, the problem-solving role played by sites, and CISCRP’s work to improve public trust in scientific advances.


    Subscribe to State of Digital Clinical Trials, a Veeva podcast, to get new episodes as soon as they are released.
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

This week, Richard Young speaks to Ken Getz, executive director and research professor at Tufts Center for the Study of Drug Development.


Already well-known in our industry for his pioneering research on protocol design complexity and trial efficiency, Ken’s most recent study found that the average number of amendments per protocol increased by almost 60% over the past seven years.


In this episode, Richard and Ken debate whether clinical research is striking the right balance in its approach to risk and innovation, the problem-solving role played by sites, and CISCRP’s work to improve public trust in scientific advances.


Subscribe to State of Digital Clinical Trials, a Veeva podcast, to get new episodes as soon as they are released.
生物科学
続きを読む 一部表示

Are We Too Risk Averse in Clinical Research?に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。